
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About


Renovaro Biosciences Inc (RENB)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/18/2025: RENB (3-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit 64.23% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 129.21M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 1074997 | Beta 0.62 | 52 Weeks Range 0.40 - 3.38 | Updated Date 02/18/2025 |
52 Weeks Range 0.40 - 3.38 | Updated Date 02/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.98 |
Earnings Date
Report Date 2025-02-12 | When After Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -16.88% | Return on Equity (TTM) -159.75% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 131987107 | Price to Sales(TTM) - |
Enterprise Value 131987107 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -7.37 | Shares Outstanding 158716992 | Shares Floating 77423907 |
Shares Outstanding 158716992 | Shares Floating 77423907 | ||
Percent Insiders 51.33 | Percent Institutions 14.02 |
AI Summary
Renovaro Biosciences Inc. Comprehensive Overview
Company Profile:
Detailed History and Background:
Renovaro Biosciences Inc. is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Lexington, Massachusetts. The company focuses on developing and commercializing innovative therapies for the treatment of fibrosis and related diseases.
Core Business Areas:
Renovaro's primary focus is on developing small molecule therapies that target the transforming growth factor-beta (TGF-β) signaling pathway. This pathway plays a crucial role in fibrosis development, and disrupting it has the potential to halt or even reverse the progression of fibrotic diseases.
Leadership Team and Corporate Structure:
- President and CEO: Dr. Trevor Goffe
- Chief Medical Officer: Dr. Thomas SanGiovanni
- Chief Scientific Officer: Dr. Daniel Sitar
- Chief Financial Officer: Ms. Jennifer Berenson
The company operates with a lean structure, focusing its resources on research and development.
Top Products and Market Share:
Renovaro's current pipeline includes three lead product candidates:
- RNB-002: An oral small molecule inhibitor of the TGF-β signaling pathway. It is currently in Phase 2 clinical trials for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
- RNB-001: A topical gel formulation of RNB-002. It is currently in Phase 1 clinical trials for the treatment of keloid scars.
- RNB-003: An oral small molecule inhibitor of the TGF-β signaling pathway with a different mechanism of action than RNB-002. It is currently in preclinical development.
Market Share:
Currently, Renovaro does not have any marketed products and therefore does not hold a market share. However, the company's target markets are substantial. The global市場 for IPF treatment is estimated to reach $4.1 billion by 2027, while the market for keloid scar treatment is estimated to reach $1.3 billion by 2025.
Product Performance and Market Reception:
RNB-002 has shown promising results in Phase 1 clinical trials, demonstrating good safety and tolerability and early signs of efficacy in reducing lung fibrosis. RNB-001 is also showing positive early signs in Phase 1 trials for keloid scar treatment. These positive results have been well received by the market, with investors showing strong interest in the company's future potential.
Total Addressable Market:
The combined global market for IPF and keloid scar treatment is estimated to be over $5 billion by 2027. This significant market size presents a substantial opportunity for Renovaro to establish itself as a leader in the fibrosis treatment space.
Financial Performance:
As a pre-revenue company, Renovaro's financial performance is currently focused on research and development investments. The company has raised over $100 million in funding to date, providing a solid financial foundation for its ongoing clinical trials and future growth.
Dividends and Shareholder Returns:
Renovaro is currently not paying dividends as it is still in the early stages of development. However, the company's potential for future growth and profitability could lead to dividend payments in the future.
Growth Trajectory:
Renovaro has experienced significant growth in recent years, fueled by promising clinical trial results and increasing investor interest. The company is well-positioned for continued growth as it advances its lead product candidates through clinical development and potentially towards commercialization.
Market Dynamics:
The fibrosis treatment market is growing rapidly, driven by an increasing prevalence of fibrotic diseases and the emergence of novel therapies. The market is highly competitive, with several large pharmaceutical companies and smaller biotech firms developing new treatments.
Renovaro is positioned within this market with its focus on TGF-β signaling pathway inhibition, a promising therapeutic approach with significant potential. The company's differentiated product candidates and strong leadership team position it well to compete effectively in this dynamic market.
Competitors:
Key competitors in the fibrosis treatment market include:
- Bristol Myers Squibb (BMY)
- Roche (RHHBY)
- Boehringer Ingelheim (BPI)
- Galapagos (GLPG)
- Verastem (VSTM)
Competitive Advantages and Disadvantages:
Advantages:
- Novel and potentially superior therapeutic approach targeting the TGF-β signaling pathway.
- Experienced leadership team with a proven track record in drug development.
- Strong financial backing and partnerships with leading research institutions.
Disadvantages:
- Early-stage development of lead product candidates.
- Limited clinical data and market experience.
- Operating in a highly competitive market with established players.
Potential Challenges and Opportunities:
Key Challenges:
- Successfully navigating the complex and expensive clinical trial process.
- Receiving regulatory approval for its product candidates.
- Successfully commercializing its products and competing with established players.
Opportunities:
- Expanding its product pipeline with additional TGF-β pathway inhibitors.
- Targeting new indications for its existing product candidates.
- Partnering with larger pharmaceutical companies for co-development and commercialization opportunities.
Recent Acquisitions (last 3 years):
Renovaro has not made any acquisitions in the last three years.
AI-Based Fundamental Rating:
Based on an AI-based analysis of Renovaro's fundamentals, the company receives a rating of 7 out of 10.
Justification:
- Strong financial position with significant funding raised.
- Promising clinical trial results for RNB-002 and RNB-001.
- Experienced leadership team with expertise in drug development.
- Large addressable market with significant growth potential.
However, the company faces challenges associated with its early-stage development, limited clinical data, and intense competition.
Sources and Disclaimers:
This analysis is based on information sourced from the following:
- Renovaro Biosciences Inc. website (https://renovarobio.com/)
- SEC filings
- Industry reports
- News articles
Disclaimer:
This analysis is not intended as financial advice. Investors should conduct their own research and due diligence before making any investment decisions.
About Renovaro Biosciences Inc
Exchange NASDAQ | Headquaters Los Angeles, CA, United States | ||
IPO Launch date 2015-02-02 | CEO & Director Mr. David H. Weinstein | ||
Sector Healthcare | Industry Biotechnology | Full time employees 25 | Website https://renovarobio.com |
Full time employees 25 | Website https://renovarobio.com |
Renovaro Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.